Document Detail

Potential new treatments for type 2 diabetes.
MedLine Citation:
PMID:  10871894     Owner:  NLM     Status:  MEDLINE    
The heterogeneous pathogenesis and progressive natural history of type 2 diabetes mellitus (T2DM) contrive a formidable therapeutic challenge. Dual endocrine deficits of impaired insulin action (insulin resistance) and inadequate insulin secretion create an environment of chronic hyperglycaemia and general metabolic disarray. This inflicts a heavy burden of morbidity and premature mortality from cardiovascular diseases, microvascular disorders (e.g. retinopathy and nephropathy) and neuropathic conditions. Improving glycaemic control delays the onset and reduces the severity of these long-term complications. However, even with intensive use of current antidiabetic agents more than 50% of T2DM patients suffer poor glycaemic control and 18% develop serious complications within six years of diagnosis. Clearly, there is a need for new antidiabetic agents.
C J Bailey
Related Documents :
25201774 - Nutrition for the prevention and treatment of chronic kidney disease in diabetes.
23824324 - Diabetes mellitus associated with clomipramine treatment: a retrospective analysis.
23130654 - Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and t...
24170754 - Increased glycemic variability is independently associated with length of stay and mort...
20876714 - Diminished superoxide generation is associated with respiratory chain dysfunction and c...
17599854 - Exaggeration of postprandial hyperglycemia in patients with type 2 diabetes by administ...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Trends in pharmacological sciences     Volume:  21     ISSN:  0165-6147     ISO Abbreviation:  Trends Pharmacol. Sci.     Publication Date:  2000 Jul 
Date Detail:
Created Date:  2000-09-05     Completed Date:  2000-09-05     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7906158     Medline TA:  Trends Pharmacol Sci     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  259-65     Citation Subset:  IM    
School of Life and Health Sciences, Aston University, Birmingham, UK B4
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Glucose / drug effects,  physiology*
Diabetes Mellitus, Type 2 / drug therapy*,  physiopathology
Hyperglycemia / drug therapy,  metabolism
Hypoglycemic Agents / pharmacology,  therapeutic use*
Insulin / metabolism*,  therapeutic use
Insulin Resistance / physiology
Islets of Langerhans / drug effects,  metabolism*
Thiazoles / therapeutic use
Reg. No./Substance:
0/Blood Glucose; 0/Hypoglycemic Agents; 0/Thiazoles; 0/Thiazolidinediones; 11061-68-0/Insulin; 2295-31-0/2,4-thiazolidinedione

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Glutamate receptors in glia: new cells, new inputs and new functions.
Next Document:  Fluorescence techniques: shedding light on ligand-receptor interactions.